Oncocyte Corp Appoints New Directors, Reports Executive Compensation
Ticker: IMDX · Form: 8-K · Filed: May 23, 2024 · CIK: 1642380
Sentiment: neutral
Topics: board-of-directors, executive-compensation, governance
TL;DR
Oncocyte added two directors and filed on exec pay. Board changes could mean strategy shifts.
AI Summary
On May 20, 2024, Oncocyte Corporation announced the election of Dr. Michael J. McShane and Mr. David L. Briones to its Board of Directors. Additionally, the company reported on compensatory arrangements for its named executive officers, though specific details of these arrangements were not provided in this filing.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, while executive compensation details are crucial for understanding how leadership is incentivized.
Risk Assessment
Risk Level: medium — Board changes and executive compensation disclosures are significant governance events that can impact investor confidence and future company direction.
Key Players & Entities
- Oncocyte Corporation (company) — Registrant
- Dr. Michael J. McShane (person) — Newly elected Director
- Mr. David L. Briones (person) — Newly elected Director
- May 20, 2024 (date) — Date of earliest event reported
FAQ
Who were the individuals elected to Oncocyte Corporation's Board of Directors?
Dr. Michael J. McShane and Mr. David L. Briones were elected to the Board of Directors.
What is the date of the earliest event reported in this 8-K filing?
The earliest event reported is dated May 20, 2024.
What specific compensatory arrangements were disclosed for Oncocyte's officers?
The filing indicates that compensatory arrangements for certain officers were reported, but the specific details are not provided within this document.
What is Oncocyte Corporation's state of incorporation?
Oncocyte Corporation is incorporated in California.
What is Oncocyte Corporation's principal executive office address?
The principal executive offices are located at 15 Cushing, Irvine, California 92618.
Filing Stats: 702 words · 3 min read · ~2 pages · Grade level 13.3 · Accepted 2024-05-23 16:05:24
Key Financial Figures
- $351,525.20 — ment, Dr. Schtz's annual base salary is $351,525.20 (the "Base Salary") and he will be elig
Filing Documents
- form8-k.htm (8-K) — 37KB
- 0001493152-24-021144.txt ( ) — 204KB
- ocx-20240520.xsd (EX-101.SCH) — 3KB
- ocx-20240520_lab.xml (EX-101.LAB) — 33KB
- ocx-20240520_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ONCOCYTE CORPORATION Date: May 23, 2024 By: /s/ Joshua Riggs Joshua Riggs President and Chief Executive Officer